The development of Wy-41,195, an orally effective antiallergic drug in animal models.
D000284:Administration, Oral; D000596:Amino Acids; D000818:Animals; D001249:Asthma / Q000188:drug therapy*; D004195:Disease Models, Animal; D004285:Dogs; D006168:Guinea Pigs; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D006969:Hypersensitivity, Immediate; D007700:Kinetics; D008168:Lung / Q000187:drug effects / Q000276:immunology; D008407:Mast Cells / Q000187:drug effects / Q000502:physiology; D010072:Oxamic Acid / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D012867:Skin / Q000187:drug effects / Q000276:immunology
D000596:Amino Acids; D006634:Histamine H1 Antagonists; C031308:(2-cyano-3-(methylamino)phenyl)oxoacetic acid; D010072:Oxamic Acid